Individual sorted T cell profiling from healthy donor

Etrolizumab, a humanized monoclonal antibody that selectively binds the b7 subunit of the heterodimeric integrins a4b7 and aEb7, is currently in development for patients with moderate-to-severely active UC. Integrin aE forms a heterodimer with b7; and aEb7 interacts with E-cadherin to mediate retention of aEb7+ cells in the intestinal epithelium. Baseline integrin aE levels have been identified as a potential predictive biomarker for etrolizumab response. Materials and methods: Mucosal lymphocytes were isolated using a collagenase digestion from resected tissue from a patient without inflammatory bowel disease. Individual CD45+TCRab+TCRgd- cells were sorted into 96 well plates. Cell numbers were normalized across CD4+aE+, CD4+aE-, CD8+aE+ and CD8+aE- groups. RNA was isolated from individual CD45+TCRab+TCRgd- T cells sorted into CD4+aE+, CD4+aE-, CD8+aE+ and CD8+aE- subsets. Raw data not provided due to patient privacy concerns